modafinil has been researched along with Chronic Disease in 14 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms." | 9.16 | A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Arbabi, M; Bagheri, M; Khalighi-Sigaroudi, F; Rezaei, F; Tabrizi, M, 2012) |
| "To study the acute effects of modafinil administration upon brain activity and cognitive performance in people with chronic schizophrenia." | 9.11 | Modafinil modulates anterior cingulate function in chronic schizophrenia. ( Green, RD; Hunter, MD; Spence, SA; Wilkinson, ID, 2005) |
| "Modafinil is a wakefulness-promoting agent that the FDA has approved for the treatment of excessive daytime sleepiness associated with narcolepsy." | 5.32 | Modafinil for the treatment of pain-associated fatigue: review and case report. ( Cole, B; Cutler, RB; Fishbain, DA; Lewis, J; Rosomoff, HL; Steele-Rosomoff, R, 2004) |
| "In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms." | 5.16 | A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Arbabi, M; Bagheri, M; Khalighi-Sigaroudi, F; Rezaei, F; Tabrizi, M, 2012) |
| "To study the acute effects of modafinil administration upon brain activity and cognitive performance in people with chronic schizophrenia." | 5.11 | Modafinil modulates anterior cingulate function in chronic schizophrenia. ( Green, RD; Hunter, MD; Spence, SA; Wilkinson, ID, 2005) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| "Modafinil treatment was associated with significantly higher BART scores (p=0." | 2.79 | Preliminary evidence for normalization of risk taking by modafinil in chronic cocaine users. ( Bessette, AJ; Canavan, SV; Forselius, EL; Morgan, PT, 2014) |
| "Fatigue is a common symptom experienced by people with cancer and other long-term, non-malignant conditions." | 2.61 | The holistic management of fatigue within palliative care. ( Dean, A, 2019) |
| "The consequences of chronic insufficient sleep for health remain uncertain." | 1.46 | Decreased alertness due to sleep loss increases pain sensitivity in mice. ( Alexandre, C; Ferreira, A; Latremoliere, A; Miracca, G; Scammell, TE; Woolf, CJ; Yamamoto, M, 2017) |
| "Modafinil is a wakefulness-promoting agent that the FDA has approved for the treatment of excessive daytime sleepiness associated with narcolepsy." | 1.32 | Modafinil for the treatment of pain-associated fatigue: review and case report. ( Cole, B; Cutler, RB; Fishbain, DA; Lewis, J; Rosomoff, HL; Steele-Rosomoff, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dean, A | 1 |
| Alexandre, C | 1 |
| Latremoliere, A | 1 |
| Ferreira, A | 1 |
| Miracca, G | 1 |
| Yamamoto, M | 1 |
| Scammell, TE | 1 |
| Woolf, CJ | 1 |
| Canavan, SV | 1 |
| Forselius, EL | 1 |
| Bessette, AJ | 1 |
| Morgan, PT | 1 |
| Michalopoulou, PG | 1 |
| Lewis, SW | 1 |
| Drake, RJ | 1 |
| Reichenberg, A | 1 |
| Emsley, R | 1 |
| Kalpakidou, AK | 1 |
| Lees, J | 1 |
| Bobin, T | 1 |
| Gilleen, JK | 1 |
| Pandina, G | 1 |
| Applegate, E | 1 |
| Wykes, T | 1 |
| Kapur, S | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 1 |
| Dougall, D | 1 |
| Poole, N | 1 |
| Agrawal, N | 1 |
| Rosenthal, TC | 1 |
| Majeroni, BA | 1 |
| Pretorius, R | 1 |
| Malik, K | 1 |
| Garrison, MK | 1 |
| Yates, CC | 1 |
| Reese, NB | 1 |
| Skinner, RD | 1 |
| Garcia-Rill, E | 1 |
| Arbabi, M | 1 |
| Bagheri, M | 1 |
| Rezaei, F | 1 |
| Ahmadi-Abhari, SA | 1 |
| Tabrizi, M | 1 |
| Khalighi-Sigaroudi, F | 1 |
| Akhondzadeh, S | 1 |
| Turner, DC | 1 |
| Clark, L | 1 |
| Pomarol-Clotet, E | 1 |
| McKenna, P | 1 |
| Robbins, TW | 1 |
| Sahakian, BJ | 1 |
| Fishbain, DA | 1 |
| Cutler, RB | 1 |
| Lewis, J | 1 |
| Cole, B | 1 |
| Rosomoff, HL | 1 |
| Steele-Rosomoff, R | 1 |
| Spence, SA | 1 |
| Green, RD | 1 |
| Wilkinson, ID | 1 |
| Hunter, MD | 1 |
| Piérard, C | 1 |
| Liscia, P | 1 |
| Valleau, M | 1 |
| Drouet, I | 1 |
| Chauveau, F | 1 |
| Huart, B | 1 |
| Bonneau, D | 1 |
| Jouanin, JC | 1 |
| Beaumont, M | 1 |
| Béracochéa, D | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for modafinil and Chronic Disease
| Article | Year |
|---|---|
The holistic management of fatigue within palliative care.
Topics: Central Nervous System Stimulants; Chronic Disease; Cognitive Behavioral Therapy; Complementary Ther | 2019 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury.
Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Benzhydryl Compounds; Brain Injuries; Chronic Di | 2015 |
Fatigue: an overview.
Topics: Behavior Therapy; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Chronic Disease | 2008 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
5 trials available for modafinil and Chronic Disease
| Article | Year |
|---|---|
Preliminary evidence for normalization of risk taking by modafinil in chronic cocaine users.
Topics: Adult; Benzhydryl Compounds; Chronic Disease; Cocaine-Related Disorders; Cognition; Cohort Studies; | 2014 |
Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia.
Topics: Adult; Benzhydryl Compounds; Chemotherapy, Adjuvant; Chronic Disease; Cognitive Behavioral Therapy; | 2015 |
A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Diseas | 2012 |
Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
Topics: Adult; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Benzhydryl Co | 2004 |
Modafinil modulates anterior cingulate function in chronic schizophrenia.
Topics: Adolescent; Adult; Benzhydryl Compounds; Brain Mapping; Central Nervous System Stimulants; Chronic D | 2005 |
4 other studies available for modafinil and Chronic Disease
| Article | Year |
|---|---|
Decreased alertness due to sleep loss increases pain sensitivity in mice.
Topics: Acute Disease; Analgesics; Animals; Behavior, Animal; Benzhydryl Compounds; Caffeine; Chronic Diseas | 2017 |
Wind-up of stretch reflexes as a measure of spasticity in chronic spinalized rats: The effects of passive exercise and modafinil.
Topics: Analysis of Variance; Animals; Benzhydryl Compounds; Chronic Disease; Disease Models, Animal; Electr | 2011 |
Modafinil for the treatment of pain-associated fatigue: review and case report.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Disease; Fatigue; Female; Hu | 2004 |
Modafinil-induced modulation of working memory and plasma corticosterone in chronically-stressed mice.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Disease; Corticosterone; D | 2006 |